News & Press Release
2024
- All Categories
- Announcements
- HR and Organization
- Product Information
-
- 2024-09-26 Announcements Filing Appeal with Intellectual Property High Court Related to Patent-infringement Lawsuit on “NOBELZIN® tablets 25 mg/50 mg” for Wilson’s Disease and Hypozincemia
- 2024-09-25 Announcements Marketing Approval for “Alabel® Oral 1.5 g” Succeeded by SBI Pharma
- 2024-08-08 Product Information “Zintus® Tablets 50 mg” for Hypozincemia Launch
- 2024-07-29 Product Information Launch of “Sargmalin® for inhalation 250 μg” for Autoimmune Pulmonary Alveolar Proteinosis
- 2024-07-08 Product Information “RAPALIMUS® Granule 0.2%” Launched
- 2024-03-26 Product Information “ACENOBEL® Sustained Release Tablet 500 mg” Approved for Distal Myopathy with Rimmed Vacuoles
- 2024-03-26 Product Information “Sargmalin® for inhalation 250 µg” Approved for Autoimmune Pulmonary Alveolar Proteinosis
- 2024-03-26 Product Information “Zintus® Tablets 25 mg/50 mg” Approved for Hypozincemia
- 2024-01-18 Product Information mTOR inhibitor “RAPRLIMUS®” Approved for Additional Indication for Tablets 1 mg and Additional Formulation of Granule 0.2%
- 2024-01-01 Product Information Sirolimus Gel “Xian Luo Li” Launched in China